These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 14992418)

  • 21. Gatifloxacin phase IV surveillance trial (TeqCES study) utilizing 5000 primary care physician practices: report of pathogens isolated and susceptibility patterns in community-acquired respiratory tract infections.
    Pfaller MA; Jones RN
    Diagn Microbiol Infect Dis; 2002 Sep; 44(1):77-84. PubMed ID: 12376036
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and tolerability of fluoroquinolones.
    Norrby SR; Lietman PS
    Drugs; 1993; 45 Suppl 3():59-64. PubMed ID: 7689453
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fluoroquinolones in the elderly: safety considerations.
    Stahlmann R; Lode H
    Drugs Aging; 2003; 20(4):289-302. PubMed ID: 12641485
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Antibacterial activity and pharmacological features of fluoroquinolones and considerations on their use in a nosocomial setting].
    Cornaglia G; Concan R; Arrigucci S; Novelli A
    Infez Med; 2007 Dec; 15(4):211-36. PubMed ID: 18162733
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro activity of gatifloxacin compared with gemifloxacin, moxifloxacin, trovafloxacin, ciprofloxacin and ofloxacin against uropathogens cultured from patients with complicated urinary tract infections.
    Naber KG; Hollauer K; Kirchbauer D; Witte W
    Int J Antimicrob Agents; 2000 Nov; 16(3):239-43. PubMed ID: 11091042
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antimicrobial treatment of lower respiratory tract infections in the hospital setting.
    Grossman RF; Rotschafer JC; Tan JS
    Am J Med; 2005 Jul; 118 Suppl 7A():29S-38S. PubMed ID: 15993675
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fluoroquinolone-associated anaphylaxis in spontaneous adverse drug reaction reports in Germany: differences in reporting rates between individual fluoroquinolones and occurrence after first-ever use.
    Sachs B; Riegel S; Seebeck J; Beier R; Schichler D; Barger A; Merk HF; Erdmann S
    Drug Saf; 2006; 29(11):1087-100. PubMed ID: 17061914
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expanded activity and utility of the new fluoroquinolones: a review.
    Blondeau JM
    Clin Ther; 1999 Jan; 21(1):3-40; discussion 1-2. PubMed ID: 10090423
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae.
    Saravolatz L; Manzor O; Check C; Pawlak J; Belian B
    J Antimicrob Chemother; 2001 Jun; 47(6):875-7. PubMed ID: 11389122
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Possible role for the new fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, clinafloxacin, sparfloxacin, and DU-6859a) in the treatment of anaerobic infections: review of current information on efficacy and safety.
    Goldstein EJ
    Clin Infect Dis; 1996 Dec; 23 Suppl 1():S25-30. PubMed ID: 8953103
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Study investigating the activity of several fluoroquinolones against Pseudomonas aeruginosa using the mutant prevention concentration].
    Sirvent E; Ruiz M; Rodríguez JC; Royo G
    Enferm Infecc Microbiol Clin; 2006 Dec; 24(10):603-7. PubMed ID: 17194384
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gatifloxacin: a review of its use in the management of bacterial infections.
    Perry CM; Ormrod D; Hurst M; Onrust SV
    Drugs; 2002; 62(1):169-207. PubMed ID: 11790160
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections.
    Martin SJ; Jung R; Garvin CG
    Drug Saf; 2001; 24(3):199-222. PubMed ID: 11347723
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antimicrobial activity of advanced-spectrum fluoroquinolones tested against more than 2000 contemporary bacterial isolates of species causing community-acquired respiratory tract infections in the United States (1999).
    Deshpande LM; Jones RN
    Diagn Microbiol Infect Dis; 2000 Jun; 37(2):139-42. PubMed ID: 10863108
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Musculoskeletal complications of fluoroquinolones: guidelines and precautions for usage in the athletic population.
    Hall MM; Finnoff JT; Smith J
    PM R; 2011 Feb; 3(2):132-42. PubMed ID: 21333952
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In-vitro activity of moxifloxacin and other fluoroquinolones against Chlamydia species.
    Miyashita N; Fukano H; Yoshida K; Niki Y; Matsushima T
    J Infect Chemother; 2002 Mar; 8(1):115-7. PubMed ID: 11957133
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The newer fluoroquinolones.
    Bolon MK
    Infect Dis Clin North Am; 2009 Dec; 23(4):1027-51, x. PubMed ID: 19909896
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies.
    Ball P; Stahlmann R; Kubin R; Choudhri S; Owens R
    Clin Ther; 2004 Jul; 26(7):940-50. PubMed ID: 15336463
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL).
    Barrera CM; Mykietiuk A; Metev H; Nitu MF; Karimjee N; Doreski PA; Mitha I; Tanaseanu CM; Molina JM; Antonovsky Y; Van Rensburg DJ; Rowe BH; Flores-Figueroa J; Rewerska B; Clark K; Keedy K; Sheets A; Scott D; Horwith G; Das AF; Jamieson B; Fernandes P; Oldach D;
    Lancet Infect Dis; 2016 Apr; 16(4):421-30. PubMed ID: 26852726
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of moxifloxacin for the treatment of community-acquired [corrected] complicated intra-abdominal infections in Taiwan.
    Lau YJ; Chen YH; Huang CT; Lee WS; Liu CY; Liu JW; Liu HD; Lee YJ; Chen CW; Ko WC; Hsueh PR
    J Microbiol Immunol Infect; 2012 Feb; 45(1):1-6. PubMed ID: 22244019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.